This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
ICD-10: D55.2 | Synonyms: TPI deficiency anemia, TPI deficiency, TPI1 deficiency, Triosephosphate isomerase deficiency
Triosephosphate isomerase deficiency anemia (TPI deficiency anemia) was first clinically described in 1965 by the American biochemist Schneider and colleagues. They confirmed that red blood cell TPI enzyme activity was markedly reduced in pediatric patients with hereditary nonspherocytic hemolytic anemia (HNSHA) and were the first to propose that a glycolytic enzyme deficiency was the cause of hemolytic anemia. This discovery confirmed it as a new type of hereditary hemolytic anemia distinct from the previously known pyruvate kinase deficiency and glucose-6-phosphate dehydrogenase (G6PD) deficiency.
In the 1970s, researchers gradually came to recognize that TPI deficiency anemia is not a simple blood disease. In particular, the studies of Gürgey et al. (1996) and Orosz et al. (2006, 2009) systematically demonstrated that TPI deficiency is accompanied by a progressive neuromuscular disorder. TPI deficiency anemia then began to be reclassified as a multisystem disease that widely affects not only red blood cells but also the nervous system and muscle tissue. Neurological symptoms often cause more severe disability than the anemia, which was a decisive turning point in understanding the natural course of this disease.
In the late 1990s and early 2000s, molecular genetic analysis revealed that the Glu104Asp (c.315G>C) variant is shared at a very high rate among European patients through a founder effect. In analyses including several European families from Hungary, France, and the United Kingdom, this single variant was detected in about 80% or more of all European TPI deficiency patients. This was a breakthrough in understanding the genetic epidemiology of TPI deficiency anemia, and the founder effect in specific populations within Europe plays a key role in explaining the regional distribution of the disease.
In the 21st century, it was revealed that crystallographic analysis of the TPI enzyme structure, abnormal enzyme dimerization, and protein folding instability are the core of the pathological mechanism. Studies of TPI deficiency in Drosophila and mouse models also contributed to exploring the molecular mechanism of neurotoxicity. Since the 2010s, the introduction of whole-exome sequencing (WES) and next-generation sequencing (NGS) has increased the number of reported families, and case reports following the neurological course after hematopoietic stem cell transplantation have begun to accumulate.
The direct cause of triosephosphate isomerase deficiency anemia is decreased or lost activity of triosephosphate isomerase (TPI; EC 5.3.1.1). TPI is an enzyme in cytoplasmic glycolysis that catalyzes the interconversion reaction between dihydroxyacetone phosphate (DHAP) and D-glyceraldehyde-3-phosphate (G3P). Because in glucose breakdown DHAP must be converted to G3P to enter the subsequent ATP-generating pathway, energy metabolism efficiency is greatly reduced in TPI deficiency.
When TPI function declines, the glycolytic intermediate DHAP accumulates abnormally in cells. Accumulated DHAP is converted, spontaneously or enzymatically, to the toxic metabolite methylglyoxal (MG). Methylglyoxal reacts with proteins, nucleic acids, and lipids to form advanced glycation end products (AGEs) and causes mitochondrial dysfunction, oxidative stress, and apoptosis. This methylglyoxal toxicity mechanism is currently the most widely accepted etiology for causing particularly severe damage in neurons and muscle cells.
TPI functions as a homodimer composed of two identical subunits. Pathogenic variants, especially the Glu104Asp variant, weaken the stability of the enzyme dimer interface and promote dissociation into monomers. Monomeric TPI not only lacks catalytic activity but is also vulnerable to proteolysis, so the total amount of TPI protein in the cell falls sharply. X-ray crystallography studies confirmed that such structural instability of the enzyme protein is a more important pathological mechanism than simple reduction of mRNA expression.
The causative gene of TPI deficiency anemia is TPI1 (Triosephosphate isomerase 1), located on chromosome 12p13.31. The mode of inheritance is autosomal recessive, and clinical symptoms appear only when pathogenic variants are present in both alleles. Heterozygous carriers have red blood cell TPI activity reduced to about 50% of normal but show no clinical symptoms. The TPI1 gene consists of 7 exons and spans about 14 kb.
Among variants reported in about 50 families worldwide, Glu104Asp (c.315G>C, p.Glu104Asp) is the most frequent. This variant is observed at a high frequency in patients in Europe, especially Hungary, France, Italy, and the United Kingdom, owing to a founder effect. In addition, many missense variants such as Phe240Leu, Ile170Val, Cys41Tyr, and Val231Met have been reported, and some patients are compound heterozygotes. Splicing variants and small deletions have also been rarely reported. The residual level of enzyme activity differs depending on the position and type of the variant, which explains part of the phenotypic diversity.
In general, a severe clinical phenotype appears when TPI enzyme activity falls to less than 5% of normal. However, considerable differences in the severity of neurological symptoms are observed even among patients with the same Glu104Asp homozygous variant, so environmental factors, modifier genes, and epigenetic factors are presumed to modulate disease severity in addition to the gene variant. In particular, the age of onset and rate of progression of the neuromuscular disorder show large individual differences even within families with the same variant.
TPI deficiency anemia is an ultra-rare disease with about 50 families and fewer than about 100 patients reported worldwide to date. It is known to be the second most common after pyruvate kinase (PK) deficiency among hereditary nonspherocytic hemolytic anemias (HNSHA) caused by glycolytic enzyme deficiency, but the absolute number of patients is very small. The exact prevalence is not known, and the rare disease database (Orphanet) classifies the prevalence as not estimable (unknown) or below 1/1,000,000.
Reported patients are concentrated mainly in Europe (Hungary, France, the United Kingdom, Italy, Germany) and North America (the United States). Hungary is the country where the Glu104Asp founder variant was first intensively analyzed, and relatively many cases have been reported. Individual cases have also been reported in Asia, Africa, and Latin America but are very rare. Reports from East Asia, including Korea, are extremely scarce. In regions with insufficient diagnostic infrastructure, diagnosis may not be made before death, so the actual prevalence may be higher than the reported figures.
Following the autosomal recessive inheritance pattern, there is no significant difference in the male-to-female ratio. Most patients are first diagnosed in the neonatal or infant period with jaundice and hemolytic anemia, and neurological symptoms usually begin to appear between several months and several years of age. Survival to adulthood is extremely rare, and reported adult survivors also have severe neuromuscular disorders.
Red blood cells have no mitochondria and depend entirely on glycolysis (Embden-Meyerhof pathway) for energy (ATP) production. In glycolysis, one molecule of glucose is broken down into two molecules of pyruvate, generating a net 2 ATP. When TPI is deficient, DHAP is not converted to G3P, so ATP production from one glucose molecule is reduced by half. Red blood cells use ATP for various survival functions, including maintaining the Na+/K+-ATPase pump, maintaining membrane phospholipid asymmetry, and regenerating glutathione, so ATP deficiency causes red cell membrane damage and early destruction (hemolysis).
Accumulated DHAP causes cytotoxicity through several pathways. First, DHAP is converted to methylglyoxal (MG), which causes non-enzymatic glycation reactions with proteins and damages the function of hemoglobin, membrane proteins, enzymes, and others. Second, methylglyoxal consumes glutathione (GSH), weakening oxidative defense capacity. Third, DHAP itself promotes intracellular osmotic changes and membrane lipid oxidation, accelerating hemolysis.
Neurons have a high energy demand, and motor neurons in particular must supply ATP continuously along their long axons. The main mechanisms of nervous system damage due to TPI deficiency are explained as ① neurotoxicity of methylglyoxal (glycation of neurofilament proteins, mitochondrial dysfunction), ② activation of apoptotic pathways by DHAP accumulation, and ③ impaired axonal transport due to glycolytic energy deficiency within neurons. A similar mechanism in muscle cells causes progressive muscle weakness, and loss of cerebrospinal motor neurons leads to progressive paralysis.
TPI is a ubiquitous enzyme expressed in all tissues, so decreased function can theoretically occur in all organs. However, the clinically prominent target organs are red blood cells (hemolysis), the nervous system (motor neuropathy, central nervous system dysfunction), muscle (progressive muscle weakness), and the heart (cardiomyopathy reported in some patients). TPI deficiency has also been confirmed in immune cells, and the resulting susceptibility to infection has been reported.
The first symptom to appear is anemia due to chronic hereditary nonspherocytic hemolytic anemia (HNSHA). Pathological jaundice that is hard to distinguish from physiological jaundice may occur in the neonatal period, or it may present in infancy as pallor, fatigue, feeding difficulty, and growth delay. Hyperbilirubinemia due to hemolysis can cause early cholelithiasis (gallbladder pigment stones). Under stress such as infection or fever, acute hemolytic crises may occur and the anemia can worsen rapidly. Splenomegaly arises from splenic hyperplasia due to chronic hemolysis.
The clinical particularity of TPI deficiency anemia lies in the progressive neuromuscular disorder. Delayed motor development, hypotonia, and muscle weakness begin to appear between several months and several years of age. As the disease progresses, inability to walk, limb muscle atrophy, and decreased or absent deep tendon reflexes are observed. In some patients, intellectual disability, delayed language development, and seizures are reported as central nervous system symptoms. Nerve conduction studies show a motor-predominant neuropathy with decreased motor nerve conduction velocity and decreased compound muscle action potential (CMAP) amplitude.
Cardiac involvement, such as cardiomyopathy and arrhythmia, has been reported in some patients. Increased susceptibility to infection also occurs in some cases, which may be related to decreased TPI function in leukocytes. Rare cases of testicular abnormalities or retinal degeneration have also been reported, suggesting the broad range of multisystem involvement in TPI deficiency anemia.
The most common signs observed on physical examination are pallor and jaundice. Scleral icterus reflects chronic indirect hyperbilirubinemia. Splenomegaly is variable, ranging from moderate to severe. On neurological examination, hypotonia, decreased or absent deep tendon reflexes, distal muscle weakness (especially of the lower limbs), and muscle atrophy are observed. Gait abnormalities (ataxia, steppage gait, etc.) can also appear depending on the degree of progression of the neuropathy.
On peripheral blood smear, normocytic to microcytic anemia may be seen together with red blood cell morphological abnormalities (target cells, rare spherocytes, a general nonspherocytic hemolysis pattern). Increased reticulocyte percentage, elevated indirect bilirubin, elevated LDH, and decreased haptoglobin are the typical laboratory signs of hemolytic anemia. The direct antiglobulin test (DAT, Coombs test) is negative, confirming that the hemolysis is not immune-mediated. Measurement of red blood cell TPI enzyme activity shows a value less than 5% of normal.
When the neuromuscular disorder has progressed, electromyography (EMG) and nerve conduction studies (NCS) show findings of motor neuropathy with lower limb predominance. Brain MRI may show white matter abnormalities or brain atrophy in some patients. Muscle MRI may show fatty infiltration of limb muscles. Abdominal ultrasound sometimes confirms splenomegaly and gallbladder pigment stones.
TPI deficiency anemia is not currently included in the standard newborn screening panel in most countries. Because of its ultra-rare frequency and the test cost-effectiveness issue, general population screening is not performed. However, it is considered in the differential diagnosis for neonates or infants with hemolytic anemia of unknown cause after more common causes such as G6PD deficiency and pyruvate kinase deficiency have been excluded.
In families that already have a patient with TPI deficiency anemia, screening of siblings and at-risk pregnancies is strongly recommended. When heterozygous carrier parents are identified, the fetal genotype can be confirmed in subsequent pregnancies through prenatal genetic testing (amniocentesis or chorionic villus sampling). When a variant has been identified in the family, targeted molecular analysis for that variant is the most efficient screening method.
TPI activity screening should be considered in the following clinical situations: ①chronic nonspherocytic hemolytic anemia of unknown cause (after excluding G6PD, PK, hereditary spherocytosis, etc.), ②hemolytic anemia accompanied by progressive neuromuscular disorder, ③a history of early death or undiagnosed death of a sibling who showed similar symptoms. In these cases, measurement of red blood cell TPI enzyme activity is performed as the first-line screening.
The key test for definitive diagnosis of TPI deficiency anemia is quantitative measurement of red blood cell TPI enzyme activity. The standard method uses a spectrophotometer to measure the rate of NADH consumption, and in TPI deficiency patients activity is greatly reduced to less than 5% of normal (generally 1~5%). If there is a history of recent transfusion before testing, normal TPI in donor red blood cells can make the test result falsely positive, so testing without transfusion within at least 3 months is recommended. Enzyme activity can also be measured in leukocytes and other tissues, which allows diagnosis without transfusion interference.
Sanger sequencing of the TPI1 gene is the confirmatory method for identifying pathogenic variants. In patients of European ancestry, the Glu104Asp variant is analyzed first in a targeted manner, and if it is absent, the entire coding region and exon-intron boundaries are analyzed. Recently, cases in which TPI1 variants are diagnosed through next-generation sequencing (NGS)-based nonspherocytic hemolytic anemia panel testing or whole-exome sequencing (WES) have also been increasing. Prenatal diagnosis is performed by targeted variant analysis using amniotic cell or chorionic villus cell DNA, based on the identified parental variants.
The main diseases to be differentiated from TPI deficiency anemia are as follows.
| Disease | Distinguishing points |
|---|---|
| Pyruvate kinase (PK) deficiency | Similar to HNSHA, no neuromuscular disorder, PKR gene variant |
| G6PD deficiency | X-linked, male predominance, paroxysmal hemolysis due to oxidative stress |
| Hereditary spherocytosis (HS) | Spherical red blood cells, AGLT positive, membrane protein abnormality |
| Spinal muscular atrophy (SMA) | SMN1 deletion, no hemolysis |
| Charcot-Marie-Tooth disease (CMT) | Peripheral nerve genes such as PMP22, no hemolysis |
Currently there is no curative treatment for TPI deficiency anemia except hematopoietic stem cell transplantation (HSCT), and most patients depend on conservative treatment. Packed red blood cell (pRBC) transfusion is given for symptomatic anemia due to chronic hemolytic anemia (Hb <7g/dL, or symptom-based criteria). With chronic transfusion, iron chelation therapy may be needed to prevent iron overload. Folic acid supplementation is generally recommended to compensate for folate consumption from chronic hemolysis (1~5mg per day). A management plan in preparation for acute hemolytic crises during infection or fever is also important.
Splenectomy may help reduce transfusion requirements. Because the spleen is the main organ that phagocytoses damaged red blood cells, red blood cell survival is prolonged after splenectomy and the anemia improves somewhat. However, splenectomy does not completely correct the hematologic abnormalities, and the therapeutic effect is limited in that the neuromuscular disorder continues to progress even after splenectomy. In addition, because the risk of infection by encapsulated bacteria (pneumococcus, meningococcus, Haemophilus influenzae type b) increases after splenectomy, vaccination and prophylactic antibiotics are needed.
Allogeneic hematopoietic stem cell transplantation (allogeneic HSCT) is the only treatment that can curatively correct the hematologic findings (hemolytic anemia) of TPI deficiency anemia. After transplantation, donor-derived red blood cells express normal TPI, so the hemolytic anemia disappears. However, the neuromuscular disorder tends to continue to progress even after HSCT, and the major limitation is pointed out that transplantation neither reverses nor prevents nervous system damage. Therefore, HSCT may be more advantageous the earlier it is performed, before neurological damage has progressed severely, but only a few case reports exist, so it is difficult to draw definitive conclusions about the neurological prognosis.
There is currently no evidence-based treatment for the progressive neuromuscular disorder. Physical therapy, occupational therapy, and use of assistive devices (walking aids, wheelchairs) are provided to maintain function and improve quality of life. Anticonvulsants are used when seizures are present. When respiratory muscle weakness has progressed, noninvasive positive pressure ventilation (NPPV) or ventilator support may be needed.
TPI deficiency anemia is considered one of the diseases with the poorest prognosis among hemolytic anemias due to glycolytic enzyme deficiency classified as D55.2. Most patients are diagnosed with hemolytic anemia in infancy or early childhood, and a progressive neuromuscular disorder develops within the following years. Many reported patients died in mid-childhood to adolescence because of neuromuscular complications. Patients who survived to adulthood also live dependent lives because of severe neuromuscular disorders, and respiratory failure is the main cause of death.
In patients who underwent hematopoietic stem cell transplantation, the hematologic prognosis improves, but the neuromuscular prognosis varies depending on the timing of transplantation and the degree of neurological damage before transplantation. Early transplantation (before neurological symptoms appear or at an early stage) may be advantageous for improving the neurological prognosis, but long-term follow-up data to prove this are still lacking. Summarizing the case reports so far, complete recovery of the neuromuscular disorder has not been achieved in most transplanted patients.
Drugs that activate the glyoxalase pathway targeting methylglyoxal toxicity, drugs that stabilize the TPI protein (pharmacological chaperones), and gene therapy (complementation of the TPI1 gene using a lentiviral vector) are being explored at the preclinical research level. If these approaches lead to clinical use, there is potential for improved prognosis in the future.
Because TPI deficiency anemia is an autosomal recessive genetic disease, both parents of the patient are heterozygous carriers. Between carrier parents, in each pregnancy there is a 25% chance of an affected child, 50% are carriers, and 25% are normal. Comprehensive genetic counseling for the entire patient's family is essential. Carrier testing is performed by measuring TPI enzyme activity (carriers have about 50% of normal) or by molecular genetic testing for the variant identified in the family.
For couples who are heterozygous carriers, the fetal genotype can be confirmed through prenatal genetic testing before or in early pregnancy. TPI1 variants are analyzed in fetal cell DNA obtained by chorionic villus sampling (10~13 weeks of gestation) or amniocentesis (15~20 weeks of gestation). When in vitro fertilization (IVF) is performed, implantation of affected embryos can be prevented through preimplantation genetic testing (PGT-M). Sufficient ethical and medical counseling must precede these choices.
Measures for preventing complications in diagnosed patients include ①regular hematologic monitoring (degree of anemia, transfusion interval), ②vaccination (pneumococcus, meningococcus, Hib) and prophylactic antibiotics when splenectomy is performed, ③regular abdominal ultrasound follow-up for cholelithiasis, ④regular neurological assessment of neuromuscular function, and ⑤monitoring of iron overload (ferritin, cardiac and liver MRI T2*).